About the Treatment – Semnurpharma

SP-102 (SEMDEXA ™) is a non-opioid injectable gel intended for the treatment of lumbosacral radicular pain, the most common type being sciatica.

SP-102 (SEMDEXA ™) has an ingredient which is a widely used corticosteroid solution. Corticosteroids have been given epidurally (directly into the spine) for the pain caused by sciatica since about 1970; however, there is no US FDA-approved injectable corticosteroid for sciatica.

SP-102 (SEMDEXA ™) has completed PHASE 3 C.L.E.A.R. study meeting primary and key secondary endpoints.

SP-102 (SEMDEXA™) is a treatment intended to produce an anti‑inflammatory effect from the widely used corticosteroid solution and it is intended to last longer than other steroid injections possibly used by your doctor to treat your sciatica. SP-102 (SEMDEXA™) contains no particulates and no neurotoxic preservatives, which is expected to result in a better safety profile.

26 %

of the U.S. population (20 yrs+) are affected by chronic pain*

SP-102 (SEMDEXA ™) is not able to be sold as a drug yet in the US as it has not been approved for marketing by the Food and Drug Administration (FDA) or in any other country. This study is for research purposes only and it is required if SP-102 (SEMDEXA ™) is to be approved by the regulatory agencies (like the FDA) around the world to be legally sold as a drug.

SP-102 (SEMDEXA ™) injectable gel has been given to a few research participants epidurally for the treatment of sciatica. These participants tolerated it well and had very few side effects.

Visit Clinicaltrials.gov